顧糖維緩釋錠 1000 毫克

Negara: Taiwan

Bahasa: China

Sumber: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Bahan aktif:

METFORMIN HCL (EQ TO METFORMIN HYDROCHLORIDE)

Tersedia dari:

台灣默克股份有限公司 台北市內湖區堤頂大道2段89號6樓 (23526610)

Kode ATC:

A10BA02

Bentuk farmasi:

緩釋錠

Komposisi:

METFORMIN HCL (EQ TO METFORMIN HYDROCHLORIDE) (6820400710) MG

Unit dalam paket:

鋁箔盒裝

Kelas:

製　劑

Jenis Resep:

須由醫師處方使用

Diproduksi oleh:

MERCK SANTE S.A.S. – CENTRE DE MEYZIEU 10 AVENUE DE LATTRE DE TASSIGNY 69330 MEYZIEU - FRANCE FR

Area terapi:

metformin

Indikasi Terapi:

第二型糖尿病。說明：1.成人患者於充足飲食控制及運動皆無法達到理想的血糖控制下，可選擇Glucophage XR 作為其輔助療法。2.單獨服用或與其他口服降血糖藥物或胰島素併用。

Ringkasan produk:

註銷日期: 2017/04/12; 註銷理由: 自請註銷; 有效日期: 2017/09/19; 英文品名: Glucophage XR 1000mg Prolonged Release Tablets

Status otorisasi:

已註銷

Tanggal Otorisasi:

2012-09-19

Selebaran informasi

Composition

Each Glucophage XR 500 mg prolonged release tablet contains as
active ingredient 500 mg metformin hydrochloride (equivalent to
390 mg of metformin base).
Excipients
Magnesium stearate, sodium carboxymethyl cellulose, hypromellose,
and microcrystalline cellulose.

Each Glucophage XR 750 mg prolonged release tablet contains as
active ingredient 750 mg metformin hydrochloride (equivalent to
585 mg of metformin base).
Excipients
Magnesium stearate, sodium carboxymethyl cellulose, hypromellose.

Each Glucophage XR 1000 mg prolonged release tablet contains as
active ingredient 1000 mg metformin hydrochloride (equivalent to
780 mg of metformin base).
Excipients:
Magnesium stearate, sodium carboxymethyl cellulose, hypromellose.
PROPERTIES
Glucophage XR is an antidiabetic medicine that belongs to the group
of biguanides. Metformin, the active ingredient in Glucophage
XR,
reduces
hepatic
glucose
production,
increases
insulin
sensitivity in muscles and delays intestinal glucose absorption.
A reduction of diabetic complications has been shown in overweight
type 2 diabetic adult patients treated with Glucophage immediate-
release as first-line therapy after diet therapy. Glucophage is
associated with either a stable body weight or modest weight loss.
INDICATION
Type 2 DM
1.
Glucophage XR is used for the treatment of type 2 diabetes in
adults as an adjunct to adequate diet and exercise.
2.
Glucophage XR may be given alone, or with other oral antidiabetic
agents, or with insulin.
CONTRAINDICATIONS
Glucophage XR MUST NOT BE USED in the following cases:
•
hypersensitivity to metformin hydrochloride or any of the
excipients
•
severe destabilisation of diabetes with either pre-coma or
ketoacidosis (a condition caused by substances called ‘ketone
bodies’ accumulating in the blood; symptoms include stomach
pain, fast and deep breathing, sleepiness or unusual fruity odour
of the breath)
•
renal insufficiency, as suggested by serum cleatinine leve